蓝鸟生物(BLUE)
搜索文档
bluebird bio(BLUE) - 2020 Q1 - Earnings Call Transcript
2020-05-12 10:04
bluebird bio, Inc. (NASDAQ:BLUE) Q1 2020 Results Earnings Conference Call May 11, 2020 8:00 AM ET Company Participants Ingrid Goldberg – Vice President-Investor Relations, bluebird bio, Inc. Nick Leschly – Chief Bluebird & Director, bluebird bio, Inc. David M. Davidson – Chief Medical Officer, bluebird bio, Inc. William Denise Baird – Chief Financial Officer, bluebird bio, Inc. Joanne M. Smith-Farrell – Chief Business Officer, bluebird bio, Inc. Alison C. Finger – Chief Commercial Officer, bluebird bio, Inc ...
bluebird bio(BLUE) - 2020 Q1 - Quarterly Report
2020-05-11 19:40
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 __________________________________________________________________ FORM 10-Q __________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: ...
bluebird bio(BLUE) - 2019 Q4 - Annual Report
2020-02-19 05:15
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ___________________________________________________________________________ FORM 10-K ___________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission ...
bluebird bio(BLUE) - 2019 Q3 - Quarterly Report
2019-11-01 04:48
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35966 bluebird bio, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 13-3680878 (State or Other Jurisdict ...
bluebird bio(BLUE) - 2019 Q2 - Quarterly Report
2019-08-02 04:58
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35966 bluebird bio, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 13-3680878 (State or Other Jurisdiction o ...